Pacific Edge Limited has released a shareholder letter providing an update on recent developments and strategic directions. The letter emphasizes the company's focus on capital preservation as it aims to regain Medicare coverage. Details regarding a planned Share Purchase Plan (SPP) are included, which will be offered to eligible retail shareholders at the same price as a recent placement, expected to open in mid-July. The SPP and shareholder approval of the placement are essential for maintaining momentum and responding strategically to challenges and opportunities. The letter also highlights the inclusion of Cxbladder in the American Urological Association's guideline as a significant milestone. Shareholders are encouraged to review the SPP documentation and the Notice of Annual Shareholders' Meeting to be held in Auckland on 6 August 2025. The full letter can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.